EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial

Vipul Jairath, Brian G Feagan, Mark S Silverberg, Silvio Danese, Paolo Gionchetti, Mark Löwenberg, Brian Bressler, Marc Ferrante, Ailsa Hart, Dirk Lindner, Armella Escher, Stephen Jones und 2 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.06.037 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Vipul Jairath und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv, London, Ontario, Canada. Electronic add…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Pouchitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements. METHODS: EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histologic evaluation was performed at baseline, Week (W)14, and W34. Ulcer count, adapted Simple Endoscopic Score for Crohn's Disease in the pouch, and Pouchitis Disease Activity Index histologic component were evaluated. Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 were compared by MH status at W14. RESULTS: Following treatment, mean (standard deviation) number of ulcers in vedolizumab-treated patients reduced from 15.1 (16.4) to 5.0 (4.9) at W14 and 2.7 (3.2) at W34 versus placebo-treated patients with corresponding values of 11.8 (11.3), 13.4 (18.4), and 9.7 (13.8) (vedolizumab vs placebo difference [95% confidence interval]: W14: -8.4 [-14.3, -2.6]; W34: -7.0 [-12.0, -2.0]). More patients receiving vedolizumab versus placebo achieved reduction in ulcerated pouch surface area (W14: 52.4% vs 20.0%; difference, 32.4 percentage points [p.p] [9.7, 51.4]; W34: 52.1% vs 12.9%; difference, 40.2p.p [15.6, 60.3]), absence of ulceration (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), Simple Endoscopic Score for Crohn's Disease remission (W14: 23.8% vs 7.5%; difference, 16.3p.p [1.1, 31.6]; W34: 34.4% vs 15.6%; difference, 18.8p.p [-2.0, 39.5]), and MH (W14: 16.7% vs 2.5%; difference, 14.2p.p [1.9, 26.4]). Patients with MH at W14 had higher rates of Pouchitis Disease Activity Index and Inflammatory Bowel Disease Questionnaire remission at W14 and W34 than those without. CONCLUSIONS: Vedolizumab induced endoscopic improvements in patients with chronic pouchitis, which was associated with improved outcomes at W34, particularly in patients achieving MH at W14. (ClinicalTrials.gov number, NCT02790138.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsPouchitisAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodPlacebosTreatment Outcome

Stichwörter der Autor:innen

Chronic PouchitisInflammatory Bowel DiseaseMucosal HealingUlcerative ColitisVedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsPlacebosvedolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv, London, Ontario, Canada. Electronic address: vjairath@uwo.ca.
  • Alimentiv, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital Inflammatory Bowel Disease Center, Toronto, Ontario, Canada.
  • Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
  • IRCCS Azienda Ospedaliera-Universitaria di Bologna, University of Bologna, Bologna, Italy.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Location Academic Medical Center, Amsterdam, Netherlands.

Zitieren

APA

Jairath, V., Feagan, B. G., Silverberg, M. S., Danese, S., Gionchetti, P., Löwenberg, M., Bressler, B., Ferrante, M., Hart, A., Lindner, D., Escher, A., Jones, S., Shen, B., & Travis, S. (2025). Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.06.037

Vancouver

Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, et al. Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.06.037

BibTeX
@article{Jairath2025,
  author = {Jairath, Vipul and Feagan, Brian G and Silverberg, Mark S and Danese, Silvio and Gionchetti, Paolo and Löwenberg, Mark and Bressler, Brian and Ferrante, Marc and Hart, Ailsa and Lindner, Dirk and Escher, Armella and Jones, Stephen and Shen, Bo and Travis, Simon},
  title = {Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.06.037}
}
Kostenlos starten →